Pyridone carboxamide derived compounds as soluble epoxide hydrolase inhibitors

Pyridone carboxamide compounds inhibit sEH to address the imbalance in the EET pathway, improving treatments for diabetic retinopathy and neurodegenerative diseases by increasing EET half-life and reducing vascular dysfunction and inflammation.

WO2026041679A1 Publication Date: 2026-02-26F HOFFMANN LA ROCHE & CO AG +1
2 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2025/073720
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-08-22
Filing Date
2025-08-20
Publication Date
2026-02-26

AI Technical Summary

Technical Problem

Current treatments for diabetic retinopathy, pain, and neurodegenerative diseases are inadequate, as they do not effectively address the imbalance in the EET pathway caused by soluble epoxide hydrolase (sEH), leading to vascular dysfunction, inflammation, and oxidative stress.

Method used

Development of pyridone carboxamide derived compounds that inhibit soluble epoxide hydrolase (sEH) to increase the half-life of epoxyeicosatrienoic acids (EETs), thereby mitigating the effects of sEH on diabetic retinopathy, pain, and neurodegenerative diseases.

Benefits of technology

The compounds provide a therapeutic strategy that inhibits sEH, enhancing the beneficial effects of EETs, offering potential synergistic approaches with existing therapies for diabetic retinopathy and providing relief for neuropathic pain and neurodegenerative diseases.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides new heterocyclic compounds having the general formula (I) wherein R1, R2, A, X, RA1, RA2, and RA3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
Need to check novelty before this filing date? Find Prior Art